BMY Receives EC Approval for Expanded Label of CAR T Cell Therapy Breyanzi
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Source: NASDAQ.COM
Bristol Myers Squibb Approval: The European Commission approved Breyanzi for treating adult patients with relapsed or refractory mantle cell lymphoma, marking its fourth approval in Europe for various lymphomas.
Clinical Trial Results: The approval is based on the TRANSCEND NHL 001 trial, showing an 82.7% response rate and 71.6% complete response rate among patients treated with Breyanzi.
Market Impact and Pipeline Expansion: Bristol Myers is focusing on expanding its drug pipeline due to challenges from generics affecting its legacy products, with recent share gains following positive news from Bayer's stroke prevention candidate.
Discontinuation of Librexia Study: Bristol Myers and Johnson & Johnson halted the Librexia study for milvexian after an interim analysis indicated it would not meet efficacy endpoints, but other studies for milvexian will continue as planned.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 235.270
Low
190.00
Averages
218.50
High
240.00
Current: 235.270
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nanobiotix Shares Surge on Johnson & Johnson Buyout Rumors
- Stock Price Surge: Nanobiotix (NBTX) shares rose approximately 7% in Paris following reports from La Lettre that Johnson & Johnson (JNJ) is considering a buyout, indicating strong market optimism regarding a potential deal.
- Partnership Development: The collaboration between Nanobiotix and J&J, initiated in 2023, focuses on jointly developing and commercializing their lead asset JNJ-1900 (NBTXR3), which lays a solid foundation for future growth.
- Positive Clinical Trial Feedback: Initial results from a Phase 1 trial evaluating NBTXR3 for locally advanced esophageal adenocarcinoma have garnered market attention, further driving the stock price increase and showcasing the product's market potential.
- Significant Market Capitalization Growth: Over the past year, Nanobiotix's stock has surged over 700%, resulting in a market capitalization of $1.5 billion, reflecting investor confidence in its long-term growth prospects.
See More
Jim Cramer's Warning on Tech Stocks for 2026
- Tech Stock Risk Warning: Jim Cramer has expressed concerns about the growth prospects of tech stocks, particularly AI companies, suggesting that the enthusiasm for ordinary chip and data center stocks is waning, which could expose investors to greater volatility risks.
- Market Performance Comparison: In 2026, the Nasdaq index has shown a notable decline due to the pullback in tech stocks, contrasting with the more balanced S&P 500, highlighting the importance of diversified investments to mitigate losses in any single market area.
- New AI Investment Directions: Cramer advises investors to focus on companies in traditional industries that actively deploy AI to enhance productivity and reduce costs, such as healthcare, logistics, and manufacturing, which may offer more stable investment returns.
- Preference for Blue-Chip Stocks: Cramer's recommended non-tech AI stocks include Procter & Gamble, Caterpillar, and Johnson & Johnson, which demonstrate stronger operational leverage in AI applications, making them suitable for maintaining investment durability amid market volatility.
See More
Cramer Advises Shift in AI Investment Strategy
- Market Warning: Cramer warns that the explosive growth of tech stocks over the past few years is nearing an end, particularly for ordinary chip and data center stocks, urging investors to be cautious of increasing market volatility amid regulatory and monetary policy shifts.
- Portfolio Diversification: He advises investors to focus on companies integrating AI into traditional industries such as logistics, manufacturing, and healthcare, as these firms enhance productivity and reduce costs, providing more robust investment opportunities in uncertain market conditions.
- AI Stock Picks: Cramer highlights non-tech AI stocks like Procter & Gamble (PG), Caterpillar (CAT), and Boeing (BA), suggesting these blue-chip stocks are currently more attractive than AI giants, having already experienced significant valuation expansion during the AI revolution.
- Future Outlook: While Cramer remains cautious about pure-play AI stocks, he still sees strong growth potential in Nvidia (NVDA), suggesting that investors can achieve multi-layered exposure to the AI value chain by pairing it with companies focused on workflow efficiency.
See More
Analysis of HDV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The HDV ETF's 52-week low is $106.005 per share and the high is $140.89, with the last trade at $133.24, indicating relative stability in the ETF that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable technical insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights significant inflows (new units created) or outflows (old units destroyed), which can affect the underlying holdings of the ETF and subsequently influence individual stock performance.
See More
U.S. Government Pushes for Drug Pricing Policy Legislation
- Legislative Progress: The U.S. government has begun soliciting input from drugmakers to seek legal codification of President Trump's Most Favored Nation drug pricing policy, demonstrating a commitment to reforming drug pricing.
- Pharmaceutical Participation: So far, 16 major drugmakers have agreed to lower U.S. prices of their brand-name medicines under Trump's MFN policy, which could significantly impact the pricing structure in the pharmaceutical market.
- Legislative Text Interpretation: Chris Klomp, chief counselor at the U.S. Health and Human Services, stated that the government is assisting drug companies in understanding the legislative text to seek consensus and advance policy implementation, indicating a willingness for collaboration between the government and the industry.
- Market Reaction: Despite the policy advancements, companies like Eli Lilly (LLY) are trading flat, suggesting that investors remain cautious about the potential impacts of drug pricing policies on market performance.
See More
VYM ETF: A Reliable Source of Passive Income
- Investment Return Potential: The Vanguard High Dividend Yield ETF (VYM) has averaged over 11.4% annual returns over the past decade, suggesting that a $500 monthly investment could grow to $725,220 in 25 years, yielding an annual income of $21,756, highlighting the immense potential of long-term investing.
- Diversified Portfolio: VYM includes 559 stocks across various sectors such as financials, industrials, and healthcare, with top holdings like Broadcom, JPMorgan Chase, ExxonMobil, Johnson & Johnson, and Walmart, demonstrating its broad coverage and leadership in high-dividend stocks.
- Stable Dividend Income: With an average dividend yield of around 3% over the past decade, maintaining this level could result in over $21,000 in annual dividends after 25 years, enhancing its appeal as a source of passive income.
- Low Investment Threshold: Investors can start with as little as $500 per month to achieve passive income through VYM ETF, showcasing its feasibility and strategic significance as a wealth-building tool backed by reliable dividend-paying companies.
See More
Nanobiotix Shares Surge on Johnson & Johnson Buyout Rumors
- Stock Price Surge: Nanobiotix (NBTX) shares rose approximately 7% in Paris following reports from La Lettre that Johnson & Johnson (JNJ) is considering a buyout, indicating strong market optimism regarding a potential deal.
- Partnership Development: The collaboration between Nanobiotix and J&J, initiated in 2023, focuses on jointly developing and commercializing their lead asset JNJ-1900 (NBTXR3), which lays a solid foundation for future growth.
- Positive Clinical Trial Feedback: Initial results from a Phase 1 trial evaluating NBTXR3 for locally advanced esophageal adenocarcinoma have garnered market attention, further driving the stock price increase and showcasing the product's market potential.
- Significant Market Capitalization Growth: Over the past year, Nanobiotix's stock has surged over 700%, resulting in a market capitalization of $1.5 billion, reflecting investor confidence in its long-term growth prospects.
See More
Jim Cramer's Warning on Tech Stocks for 2026
- Tech Stock Risk Warning: Jim Cramer has expressed concerns about the growth prospects of tech stocks, particularly AI companies, suggesting that the enthusiasm for ordinary chip and data center stocks is waning, which could expose investors to greater volatility risks.
- Market Performance Comparison: In 2026, the Nasdaq index has shown a notable decline due to the pullback in tech stocks, contrasting with the more balanced S&P 500, highlighting the importance of diversified investments to mitigate losses in any single market area.
- New AI Investment Directions: Cramer advises investors to focus on companies in traditional industries that actively deploy AI to enhance productivity and reduce costs, such as healthcare, logistics, and manufacturing, which may offer more stable investment returns.
- Preference for Blue-Chip Stocks: Cramer's recommended non-tech AI stocks include Procter & Gamble, Caterpillar, and Johnson & Johnson, which demonstrate stronger operational leverage in AI applications, making them suitable for maintaining investment durability amid market volatility.
See More
Cramer Advises Shift in AI Investment Strategy
- Market Warning: Cramer warns that the explosive growth of tech stocks over the past few years is nearing an end, particularly for ordinary chip and data center stocks, urging investors to be cautious of increasing market volatility amid regulatory and monetary policy shifts.
- Portfolio Diversification: He advises investors to focus on companies integrating AI into traditional industries such as logistics, manufacturing, and healthcare, as these firms enhance productivity and reduce costs, providing more robust investment opportunities in uncertain market conditions.
- AI Stock Picks: Cramer highlights non-tech AI stocks like Procter & Gamble (PG), Caterpillar (CAT), and Boeing (BA), suggesting these blue-chip stocks are currently more attractive than AI giants, having already experienced significant valuation expansion during the AI revolution.
- Future Outlook: While Cramer remains cautious about pure-play AI stocks, he still sees strong growth potential in Nvidia (NVDA), suggesting that investors can achieve multi-layered exposure to the AI value chain by pairing it with companies focused on workflow efficiency.
See More
Analysis of HDV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The HDV ETF's 52-week low is $106.005 per share and the high is $140.89, with the last trade at $133.24, indicating relative stability in the ETF that may attract investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable technical insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights significant inflows (new units created) or outflows (old units destroyed), which can affect the underlying holdings of the ETF and subsequently influence individual stock performance.
See More
U.S. Government Pushes for Drug Pricing Policy Legislation
- Legislative Progress: The U.S. government has begun soliciting input from drugmakers to seek legal codification of President Trump's Most Favored Nation drug pricing policy, demonstrating a commitment to reforming drug pricing.
- Pharmaceutical Participation: So far, 16 major drugmakers have agreed to lower U.S. prices of their brand-name medicines under Trump's MFN policy, which could significantly impact the pricing structure in the pharmaceutical market.
- Legislative Text Interpretation: Chris Klomp, chief counselor at the U.S. Health and Human Services, stated that the government is assisting drug companies in understanding the legislative text to seek consensus and advance policy implementation, indicating a willingness for collaboration between the government and the industry.
- Market Reaction: Despite the policy advancements, companies like Eli Lilly (LLY) are trading flat, suggesting that investors remain cautious about the potential impacts of drug pricing policies on market performance.
See More
VYM ETF: A Reliable Source of Passive Income
- Investment Return Potential: The Vanguard High Dividend Yield ETF (VYM) has averaged over 11.4% annual returns over the past decade, suggesting that a $500 monthly investment could grow to $725,220 in 25 years, yielding an annual income of $21,756, highlighting the immense potential of long-term investing.
- Diversified Portfolio: VYM includes 559 stocks across various sectors such as financials, industrials, and healthcare, with top holdings like Broadcom, JPMorgan Chase, ExxonMobil, Johnson & Johnson, and Walmart, demonstrating its broad coverage and leadership in high-dividend stocks.
- Stable Dividend Income: With an average dividend yield of around 3% over the past decade, maintaining this level could result in over $21,000 in annual dividends after 25 years, enhancing its appeal as a source of passive income.
- Low Investment Threshold: Investors can start with as little as $500 per month to achieve passive income through VYM ETF, showcasing its feasibility and strategic significance as a wealth-building tool backed by reliable dividend-paying companies.
See More
